home / stock / bctx / bctx articles
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("B...
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("Br...
BriaCell Therapeutics Corp (NASDAQ: BCTX) reported preliminary survival and clinical benefit data in a new subset of advanced breast cancer pa...
BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell's next generation breast and prostate cancer ...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("Br...
Dr. Adam M. Brufsky of University of Pittsburgh School of Medicine and Dr. Saranya Chumsri of Mayo Clinic will discuss the current treatment land...
BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement. TORONTO, Aug. 31, 2023 (GLOBE ...
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Corp. Company Name:
BCTX Stock Symbol:
NASDAQ Market:
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and natural killer (NK) cells The novel mechanisms of actio...
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior treatments in Bria-IMT™ population than in comparable studies Bri...